What are the differential diagnoses for a posterior fossa mass associated with elevated carcinoembryonic antigen (CEA), alpha‑fetoprotein (AFP), and beta‑human chorionic gonadotropin (β‑hCG)?

Differential Diagnoses for Posterior Fossa Mass with Elevated CEA, AFP, and β-hCG

The combination of elevated AFP, β-hCG, and CEA in a posterior fossa mass strongly suggests an intracranial germ cell tumor (GCT), specifically a mixed non-seminomatous germ cell tumor with components of embryonal carcinoma, yolk sac tumor, and/or choriocarcinoma.

Primary Differential: Intracranial Germ Cell Tumors

The constellation of all three tumor markers points definitively toward a malignant GCT. Here's the algorithmic breakdown:

Most Likely Diagnoses (in order of probability):

1. Mixed Non-Seminomatous Germ Cell Tumor (NSGCT)

• This is your top diagnosis when AFP, β-hCG, and CEA are all elevated 1
• The posterior fossa location (along with pineal and suprasellar regions) represents a classic midline extragonadal site for primary intracranial GCTs 2
• Mixed tumors containing embryonal carcinoma, yolk sac elements, and choriocarcinoma components produce this marker profile 3

2. Embryonal Carcinoma

• Produces both AFP and β-hCG 1
• CEA can be present in immature glandular components 3
• Carries poor prognosis with median survival <2 years even with treatment 1

3. Choriocarcinoma

• Primarily elevates β-hCG (often dramatically) 1, 4
• May have minor AFP elevation if mixed with other GCT elements
• Also associated with poor survival 1

Marker-Specific Interpretation:

AFP elevation indicates:

• Yolk sac tumor component (most common cause of AFP in GCTs) 4
• Embryonal carcinoma elements 1
• Critical caveat: Pure seminomas/germinomas NEVER produce AFP - any AFP elevation excludes pure seminoma regardless of histology 5

β-hCG elevation indicates:

• Choriocarcinoma component 1, 4
• Can be mildly elevated in seminomas (but not with concurrent high AFP) 4

CEA elevation indicates:

• Immature glandular/teratomatous elements within the tumor 3
• Less specific than AFP/β-hCG but supports GCT diagnosis when combined with other markers 1

Prognostic Implications

Patients with elevated AFP and/or β-hCG in intracranial GCTs have significantly worse outcomes 1:

• 5 of 7 patients with elevated markers died within 2 years
• In contrast, 4 of 7 patients with normal markers (pure germinomas) survived >5 years

Less Likely Differentials (but must exclude):

Metastatic testicular GCT:

• Check for testicular primary with ultrasound
• Extragonadal GCTs represent only 5% of all GCTs 2
• However, true primary intracranial GCTs do occur in midline structures 2

Hepatoid carcinoma (extremely rare in posterior fossa):

• Can produce AFP 6
• Would be extraordinarily unusual in this location
• Typically ovarian or gastric primary

Critical Clinical Pitfalls to Avoid:

1. Do NOT wait for tissue diagnosis if the patient is medically unstable - substantially elevated AFP and/or β-hCG in a midline mass with appropriate clinical context is sufficient to start GCT-directed chemotherapy 5

2. Normal markers do NOT exclude GCT - germinomas typically have normal AFP and β-hCG 1, 4

3. Borderline AFP elevations require cautious interpretation - false positives can occur, and minor elevations may not always reflect malignancy 5

4. CEA has low specificity - many conditions cause CEA elevation, but in combination with AFP and β-hCG in a posterior fossa mass, it supports GCT diagnosis 1

Recommended Diagnostic Approach:

• Obtain MRI brain with contrast to characterize the mass
• Measure serum AFP, β-hCG, and LDH (LDH adds prognostic value) 2, 5
• Perform testicular ultrasound to exclude gonadal primary 2
• If markers are substantially elevated and patient requires urgent treatment, chemotherapy can be initiated before biopsy 5
• If patient is stable, pursue tissue diagnosis via stereotactic biopsy
• Monitor marker half-lives after treatment initiation (AFP: 5-7 days; β-hCG: 1-3 days) 2